You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Richmond, Virginia

  • Sclerosing Cholangitis


This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for patients with primary sclerosing cholangitis (PSC). The average duration of follow-up will be approximately five years with important clinical endpoints such as death, eligibility for liver transplantation, changes in histology and cholangiogram as well as liver biochemistries and quality of life data collected.


- Chronic cholestatic disease of at least six months' duration. - Serum alkaline phosphatase at least 1 ½ times the upper limits of normal. - Retrograde, operative, percutaneous, or magnetic resonance cholangiography demonstrating intrahepatic and/or extrahepatic biliary duct obstruction, beading, or narrowing consistent with PSC within one year of the study entry. - Liver biopsy in the previous one year which is available for review and compatible with the diagnosis of PSC. Compatible biopsy features include fibrous cholangitis, ductopenia with periportal inflammation and biliary fibrosis.

Study is Available At:

Original ID:

URSO (completed)



Secondary ID:


Study Acronym:

Brief Title:

Trial of High-dose Urso in Primary Sclerosing Cholangitis

Official Title:

Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis

Overall Status:


Study Phase:

Phase 2/Phase 3



Minimum Age:

18 Years

Maximum Age:

75 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification: S

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Study Dates

Verification Date:October 2013
Last Changed Date:October 31, 2013
First Received Date:April 21, 2003

Study Outcomes

Outcome Type:Primary Outcome
Measure:To complete the evaluation of the effects of urso at a dose of 28-30 mg/kg/day on time to the development of cirrhosis, varices, cholangiocarcinoma, meeting minimal listing criteria for liver transplantation, or death in patients with PSC.
Time Frame:5 years
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Compare high dose urso vs placebo on liver biochemistries, histology stage, cholangiography, Mayo Risk Score, quality of life, toxicity, tolerability, development of cholangitis. Establish a serum, tissue & data bank for future studies.
Time Frame:5 years
Safety Issues:True

Study Interventions

Intervention Type:Drug
Name:Ursodeoxycholic Acid

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.